<DOC>
	<DOCNO>NCT01321385</DOCNO>
	<brief_summary>RATIONALE : Studying sample bone marrow patient cancer laboratory may help doctor predict well patient respond treatment . PURPOSE : This research trial study biomarkers predict response treatment bone marrow sample young patient acute myeloid leukemia .</brief_summary>
	<brief_title>Biomarkers Predicting Response Treatment Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To validate accuracy pre-specified acute myeloid leukemia ( AML ) induction response classifier My Profileâ„¢ AML Induction Therapy Assay ( run Good Laboratory Practice [ GLP ] laboratory use Good Manufacturing Practice [ GMP ] reagent ) predict response cytarabine-based induction chemotherapy pediatric patient non-M3 AML . Secondary - To validate continuous score pre-specified induction response classifier predictor response induction chemotherapy , control simultaneous effect clinical variable base-line and/or pre-induction therapy ( e.g. , age , WBC , percentage [ % ] blast ) , test commonly available start induction therapy ( e.g. , cytogenetics molecular marker ) . - To validate accuracy pre-specified induction response classifier binary predictor induction response use pre-specified cutpoint assign patient response ( NR ) complete response ( CR ) group . - To validate accuracy pre-specified induction response classifier binary predictor induction response use pre-specified cutpoint assign patient NR CR group , control simultaneous effect clinical variable base-line ( pre-induction therapy ) ( e.g. , age , WBC , % blast ) clinical variable , include test commonly available start induction therapy ( e.g. , age , WBC , cytogenetics ) . OUTLINE : Cryopreserved bone marrow mononuclear cell specimen analyze cell network profile assay . Results compare patient outcome demographic COG-AAML03P1 COG-AAML0531 study . Molecular marker analyze include Flt3ITD , NPM1 , CEBPA , MRA .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute myeloid leukemia ( AML ) NonM3 AML Cryopreserved bone marrow mononuclear cell specimen patient enrol COGAAML03P1 COGAAML0531 collect prior cytarabinebased induction therapy Patient sample COGAAML0531 must come control arm ( i.e. , gemtuzumab ozogamicin induction therapy ) PATIENT CHARACTERISTICS : No Down syndrome PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
	<keyword>childhood acute monoblastic leukemia ( M5a )</keyword>
	<keyword>childhood acute monocytic leukemia ( M5b )</keyword>
	<keyword>childhood acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>childhood acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>childhood acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>childhood acute minimally differentiate myeloid leukemia ( M0 )</keyword>
</DOC>